Imatinib sensitizes CLL lymphocytes to chlorambucil
| Autor: | Lawrence Panasci, Moulay A. Alaoui-Jamali, Loignon M, Zhiyuan Xu, Grzywacz K, Raquel Aloyz |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Cancer Research
Chronic lymphocytic leukemia Apoptosis Piperazines Therapeutic index immune system diseases hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols Tumor Cells Cultured medicine Humans Neoplasm Enzyme Inhibitors Phosphorylation Kinase activity Proto-Oncogene Proteins c-abl neoplasms Chlorambucil business.industry Cell Cycle Drug Synergism Imatinib Hematology Protein-Tyrosine Kinases medicine.disease Leukemia Lymphocytic Chronic B-Cell DNA-Binding Proteins Leukemia Pyrimidines Imatinib mesylate Oncology Drug Resistance Neoplasm Benzamides Imatinib Mesylate Cancer research Rad51 Recombinase business medicine.drug |
| Zdroj: | Leukemia. 18:409-414 |
| ISSN: | 1476-5551 0887-6924 |
| DOI: | 10.1038/sj.leu.2403247 |
| Popis: | The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10- and two-fold, respectively, to CLB. Furthermore, in primary cultures of malignant B-lymphocytes obtained from 12 patients with CLL (seven patients were untreated and five treated with CLB), imatinib synergistically sensitized these lymphocytes from two- to 20-fold to CLB. This synergistic effect was observed at concentrations of imatinib ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|